Clinical trials: Metastatic Breast Carcinoma
Breast Cancer
Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.
The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment
- Trial name
- CHEOPS (NCT02585388)
- Testing
- Vinorelbine, Letrozole, Anastrozole
- Where
- 47 sites in France
- Volunteers
- 120 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovarian Cancer, Breast Cancer
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic…
- Trial name
- SOLI (NCT04330040)
- Testing
- Olaparib
- Where
- 16 sites in India
- Volunteers
- 202 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
This is a randomized, double-blinded, multicenter phase 3 clinical trial to evaluate the efficacy and safety of pyrotinib plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel in patients who have HER2…
- Trial name
- NCT03863223
- Testing
- Pyrotinib, Trastuzumab, Docetaxel
- Where
- China
- Volunteers
- 590 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Triple Negative Metastatic Breast Cancer
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).
- Trial name
- NCT01069796
- Testing
- Paclitaxel, Bevacizumab, Capecitabine
- Where
- 17 sites in France
- Volunteers
- 64 people
- Sponsor
- ARCAGY/ GINECO GROUP
Breast Neoplasms
Prediction of Axillary Lymph Node Metastasis Status in Breast Cancer Based on PET/CT Radiomics
Patients with suspected breast cancer undergoing PET/CT at our hospital. The PET/CT center's chief physician and senior attending physician reviewed the films together and disagreement, if any, was resolved by consensus.
- Trial name
- NCT05826197
- Testing
- Radiomics
- Volunteers
- 100 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Breast Neoplasms
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC)…
- Trial name
- NCT06926868
- Testing
- Iza-bren, Nab-paclitaxel, Paclitaxel
- Where
- 295 sites in United States, Argentina and 26 more
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
The epirubicin/docetaxel combination is one of the most active and best tolerated taxane/anthracycline combinations. In this phase II trial, we will further evaluate the feasibility, safety and effectiveness of the…
- Trial name
- NCT00193024
- Testing
- Docetaxel, Epirubicin
- Volunteers
- 90 people
- Sponsor
- SCRI Development Innovations, LLC
Disseminated HER2+ Breast Cancer
Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy
This is an observational, cross-sectional study that the main objective is to describe the patient clinical profile that begins with disseminated Her 2+ Breast Cancer or develops a metastasis after or during the adjuvant…
- Trial name
- PRIMHER (NCT01645059)
- Where
- 39 sites in Spain
- Volunteers
- 129 people
- Sponsor
- Asociación Cacereña para la Investigación y el Desarrollo en Oncología Médica
Cancer
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
RATIONALE: Donor mesenchymal stem cell infusion may be an effective treatment for acute or chronic graft-versus-host disease caused by a donor stem cell transplant.
- Trial name
- NCT00361049
- Testing
- graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Neoplasms, Breast Cancer
Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer
The purpose of this study is to determine the safety and efficacy of the investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab as treatment for hormone therapy refractory Her-2/neu 1+ or 2+ expressing…
- Trial name
- IV REXBC 02 (NCT00351858)
- Testing
- ertumaxomab
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Neovii Biotech
ER+, HER2-, Metastatic Breast Cancer
AZD9833 China PK Study
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Chinese patients with ER Positive, HER2 Negative, Metastatic Breast Cancer
- Trial name
- AZD9833 (NCT04818632)
- Testing
- AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus
- Where
- 4 sites in China
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Breast Neoplasms, Breast Diseases
Clinical Evaluation of Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer
This is a study to evaluate the incidence of sampling bias during pathologic assessment of sentinel lymph nodes (SLN) when they are cut at a certain thickness (1 mm) and the tissue slices are completely analyzed by histopathology…
- Trial name
- NCT01140763
- Testing
- Sysmex's 5-blade lymph node cutter
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Sysmex America, Inc.
Doxorubicin Adverse Reaction, Cardiomyopathies, Secondary
The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor
This study looks to find a causative or predictive aspect of the suPAR biomarker for heart failure in breast cancer patients receiving Doxorubicin drug chemo regimen.
- Conditions
- Doxorubicin Adverse Reaction, Cardiomyopathies, Secondary, Breast Cancer
- Trial name
- NCT03505164
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Rush University Medical Center
Gynecologic Cancer, Gynecologic Neoplasms
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Background: Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms
- Trial name
- NCT05185947
- Testing
- Paclitaxel, Nilotinib, ECG
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
The purpose of this study is to find out the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) of JNJ-101684362 (HLD-0117), to evaluate the safety of JNJ-101684362 (HLD-0117) , and how well the…
- Trial name
- HLD-0117 (NCT07524855)
- Testing
- JNJ-101684362 (HLD-0117)
- Where
- 6 sites in United States
- Volunteers
- 170 people
- Sponsor
- Janssen Research & Development, LLC
TNBC, Triple Negative Breast Cancer, Brain Metastasases
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
This is an open-label, prospective, two-arm, multicenter phase II clinical trial. The aim is to explore the efficacy and safety of radiotherapy combined with cisplatin/carboplatin, adebrelimab, and bevacizumab in patients with…
- Trial name
- ABC-R (NCT07638852)
- Testing
- Radiation Therapy, Adebelimab, Bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Breast Cancer
Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00005963
- Testing
- carboplatin, docetaxel
- Where
- 21 sites in United States
- Volunteers
- 53 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Triple Negative Breast Cancer (TNBC)
Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who…
- Trial name
- NCT05555706
- Testing
- B013+Nab-Paclitaxel
- Where
- 13 sites in China
- Volunteers
- 62 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Breast Cancer
Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer
The purpose of this study is to assess the effectiveness and safety profile of Aiyi®(Tegafur Gimeracil Oteracil Potassium Capsule, TS-1) as a second line therapy in Chinese female patients with advanced metastatic breast cancer.
- Trial name
- NCT01492543
- Testing
- Tegafur Gimeracil Oteracil Potassium Capsule
- Where
- 7 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese Academy of Medical Sciences
Malignant Neoplasm of Breast TNM Staging Distant Metastasis (M), Untreated Bone Metastases
NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer
This study will look at two new technologies being developed for measuring cancer in bones. One of these technologies is a substance called Sodium Fluoride (NaF). Fluoride is a normal body substance.
- Trial name
- NCT02103634
- Testing
- NaF PET/MRI, NaF PET/CT, FDG PET/CT
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.